论文部分内容阅读
目的了解新诊断Graves病患者肝功能异常的发病率,分析其与甲状腺激素及抗体水平的关系。方法对102例新诊断Graves病患者用药前进行甲状腺功能、甲状腺自身抗体及肝功能等检查,剔除病毒性肝炎、脂肪肝等其他病因引起的肝功能异常患者,按肝功能正常与否分为正常组和异常组。结果 102例新诊断Graves病患者合并肝功能异常者41例,发生率为40.2%,肝功能异常组游离三碘甲状腺原氨酸(FT3)、游离四碘甲原氨酸(FT4)及促甲状腺受体抗体(TRAb)水平明显高于肝功能正常者(P<0.001),而促甲状腺素(TSH)、TGAb两组间比较差异无统计学意义。结论新诊断Graves病患者合并肝功能异常发病率高,与患者的甲状腺激素水平、TRAb水平密切相关。
Objective To understand the incidence of abnormal liver function in patients with newly diagnosed Graves’ disease and analyze its relationship with thyroid hormones and antibody levels. Methods Totally 102 patients with newly diagnosed Graves’ disease were tested for thyroid function, thyroid autoantibodies and liver function before treatment. Patients with abnormal liver function caused by other etiologies such as viral hepatitis and fatty liver were divided into normal Group and Abnormal group. Results A total of 102 cases of newly diagnosed Graves’ disease with liver dysfunction were found in 41 cases (40.2%), free triiodothyronine (FT3), free tetraiodothyronine (FT4) and thyrotropin Receptor antibody (TRAb) levels were significantly higher than normal liver function (P <0.001), while thyrotropin (TSH), TGAb no significant difference between the two groups. Conclusions The newly diagnosed patients with Graves’ disease have a high incidence of abnormal liver function, which is closely related to thyroid hormone level and TRAb level.